Insmed, Inc. (INSM): Price and Financial Metrics

Insmed, Inc. (INSM)

Today's Latest Price: $33.61 USD

0.15 (0.45%)

Updated Sep 25 4:00pm

Add INSM to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

INSM Stock Summary

  • INSM has a higher market value than 72.82% of US stocks; more precisely, its current market capitalization is $3,410,775,738.
  • INSM's price/sales ratio is 20.8; that's higher than the P/S ratio of 92.97% of US stocks.
  • Revenue growth over the past 12 months for INSMED Inc comes in at 165.68%, a number that bests 96.48% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to INSMED Inc, a group of peers worth examining would be URG, KN, HLIT, IIVI, and NSTG.
  • Visit INSM's SEC page to see the company's official filings. To visit the company's web site, go to
INSM Daily Price Range
INSM 52-Week Price Range

INSM Stock Price Chart Technical Analysis Charts

INSM Price/Volume Stats

Current price $33.61 52-week high $35.32
Prev. close $33.46 52-week low $12.09
Day low $32.93 Volume 746,294
Day high $33.85 Avg. volume 1,147,897
50-day MA $28.71 Dividend yield N/A
200-day MA $25.19 Market Cap 3.41B

Insmed, Inc. (INSM) Company Bio

Insmed Incorporated is a biopharmaceutical company focused on developing targeted inhaled therapies for patients suffering from rare lung diseases. The company was founded in 1999 and is based in Bridgewater, New Jersey.

INSM Latest News Stream

Event/Time News Detail
Loading, please wait...

INSM Latest Social Stream

Loading social stream, please wait...

View Full INSM Social Stream

Latest INSM News From Around the Web

Below are the latest news stories about INSMED Inc that investors may wish to consider to help them evaluate INSM as an investment opportunity.

OSI Systems Receives $59 Million Contract to Provide Security Inspection Systems to Hamad International Airport

OSI Systems, Inc. (the "Company" or "OSI Systems") (NASDAQ: OSIS) today announced that its Security division was awarded a contract from the Qatar Company for Airports Operation and Management ("MATAR") for approximately $59 million to provide hold (or checked) baggage screening systems, trace detection systems, and related services for the Hamad International Airport ("HIA") in Qatar. Under the terms of the award, the Company will supply its high-speed Rapiscan® RTT®110 for baggage screening along with its Itemizer® 4DX desktop trace detection system and has commenced deliveries.

Yahoo | September 24, 2020

Insmed to Present at Three September Conferences

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor conferences:

Yahoo | September 9, 2020

OSI Systems Receives Orders for $6 Million for Electronic Components

OSI Systems, Inc. (NASDAQ: OSIS) today announced that its Optoelectronics and Manufacturing division has received orders for approximately $6 million to provide electronic sub-assemblies for a leading information security technology provider OEM.

Yahoo | September 8, 2020

Loss-Making Insmed Incorporated (NASDAQ:INSM) Expected To Breakeven

With the business potentially at an important milestone, we thought we'd take a closer look at Insmed Incorporated's...

Yahoo | September 7, 2020

New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results from the Phase 2 WILLOW study of brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE) were published online in the New England Journal of Medicine (NEJM). New data from subgroup analyses of the WILLOW study also were presented today during a late-breaking clinical trials session at the virtual European Respiratory Society (ERS) International Congress 2020. Brensocatib is a novel, first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of bronchiectasis and other inflammatory diseases.

Yahoo | September 7, 2020

Read More 'INSM' Stories Here

INSM Price Returns

1-mo 16.78%
3-mo 25.13%
6-mo 109.67%
1-year 83.96%
3-year 9.84%
5-year 92.94%
YTD 40.75%
2019 82.01%
2018 -57.92%
2017 135.68%
2016 -27.11%
2015 17.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8181 seconds.